Xencor Receives Milestone Payment for Xtend™ Antibody

            Xencor Receives Milestone Payment for Xtend™ Antibody

PR Newswire

MONROVIA, Calif., Jan. 17, 2013

MONROVIA, Calif., Jan. 17, 2013 /PRNewswire/ --Xencor, Inc. today announced
it has received a milestone payment from Janssen Research & Development, LLC
(Janssen R&D) resulting from the exercised option for the use of Xencor's
Xtend™ half-life extension technology in a therapeutic antibody. This
triggered a payment to Xencor under the terms of a technology license
agreement that the company entered into with Janssen R&D (f/k/a Centocor
Research & Development, Inc.) in 2009. The antibody target and the amount of
the payment were not disclosed.

"There has been significant interest in Xtend technology because of the impact
it has on the pharmacokinetic properties of antibodies, and we are seeing
Xencor technology license agreements with partners translate into promising
pipeline programs," said Bassil Dahiyat, Ph.D., president and CEO of Xencor.

Using its Xtend technology, Xencor has developed an extensive pipeline of
best-in-class proprietary and partnered antibody therapeutics, as well as
biosuperior versions of blockbuster antibody drugs.

About Xtend™ technology
Xencor's proprietary Xtend™ antibody technology platform provides a validated
solution to enhancing the serum half-life of immunoglobulin molecules.Using
its proprietary series of antibody Fc variants, antibody half-life can be
readily prolonged to enhance performance in a number of different therapeutic
indications. By prolonging the serum half-life of antibody drug molecules the
opportunity arises to address chronic indications with an antibody drug
product that potentially i) enhances drug exposure and patient responses, ii)
is administered at more than monthly intervals, greatly enhancing patient
convenience, reducing administration costs and improving market positioning,
and iii) has a reduced dose required to maintain effective drug levels,
potentially improving the cost, profitability and capital expense profile of
the product.

About Xencor, Inc.
Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein
Design Automation® technology platform, and is a leader in the field of
antibody engineering to significantly improve antibody half-life,
immune-regulatory function and potency. The company is advancing multiple
XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting
CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513
for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio
of biosuperior versions of blockbuster antibody drugs engineered for superior
half-life and dosing schedule. Xencor has entered into multiple partnerships
with industry leaders such as Amgen, Pfizer, MorphoSys, Boehringer Ingelheim,
CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying
its suite of proprietary antibody Fc domains to improve antibody drug
candidates for traits such as sustained half-life and/or potency. For more
information, please visit www.xencor.com.

SOURCE Xencor, Inc.

Website: http://www.xencor.com
Contact: Jason I. Spark, Canale Communications for Xencor, +1-619-849-6005,
jason@canalecomm.com
 
Press spacebar to pause and continue. Press esc to stop.